Minerva Neurosciences (NERV) Research & Development (2013 - 2026)
Minerva Neurosciences posted quarterly Research & Development of $5.3 million for Q1 2026, up 285.7% year-on-year from $1.4 million in Q1 2025, and up 141.76% on a QoQ basis from $2.2 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Research & Development data on file, last reported at $5.3 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 285.7% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (up 6.14% YoY), and the FY2025 full-year result was $5.8 million, down 51.6% from the prior year.
- Research & Development for Q1 2026 stood at $5.3 million, up from $2.2 million in the prior quarter.
- Across five years, Research & Development topped out at $5.3 million in Q1 2026 and bottomed at $925377.0 in Q3 2025.
- The 5-year median for Research & Development is $2.7 million (2023), against an average of $3.0 million.
- The widest annual swing landed in 2022, when Research & Development plunged 82.98%; it then surged 285.7% in 2026.
- A 5-year view of Research & Development shows it stood at $3.2 million in 2022, then soared by 47.99% to $4.7 million in 2023, then slumped by 58.0% to $2.0 million in 2024, then climbed by 9.62% to $2.2 million in 2025, then surged by 141.76% to $5.3 million in 2026.
- The last three Research & Development figures came in at $5.3 million (Q1 2026), $2.2 million (Q4 2025), and $925377.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 925,377.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 3.86 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 2.37 Mn |
| Jun 30, 2022 | 4.13 Mn |
| Mar 31, 2022 | 4.96 Mn |
| Dec 31, 2021 | 18.75 Mn |
| Sep 30, 2021 | 4.51 Mn |
| Jun 30, 2021 | 5.52 Mn |
| Mar 31, 2021 | 3.26 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Sep 30, 2020 | 4.64 Mn |
| Jun 30, 2020 | 5.77 Mn |
| Mar 31, 2020 | 8.08 Mn |
| Dec 31, 2019 | 28.52 Mn |
| Sep 30, 2019 | 9.67 Mn |
| Jun 30, 2019 | 8.32 Mn |
| Mar 31, 2019 | 11.61 Mn |
| Dec 31, 2018 | 9.01 Mn |
| Sep 30, 2018 | 8.37 Mn |
| Jun 30, 2018 | 9.06 Mn |
| Mar 31, 2018 | 8.45 Mn |
| Dec 31, 2017 | 6.54 Mn |
| Sep 30, 2017 | 8.96 Mn |
| Jun 30, 2017 | 7.14 Mn |
| Mar 31, 2017 | 7.61 Mn |
| Dec 31, 2016 | 6.50 Mn |
| Sep 30, 2016 | 5.85 Mn |
| Jun 30, 2016 | 2.71 Mn |
| Mar 31, 2016 | 5.37 Mn |
| Dec 31, 2015 | 6.26 Mn |
| Sep 30, 2015 | 3.83 Mn |
| Jun 30, 2015 | 4.48 Mn |
| Mar 31, 2015 | 3.96 Mn |
| Dec 31, 2014 | 2.97 Mn |
| Sep 30, 2014 | 24.74 Mn |
| Jun 30, 2014 | 14.55 Mn |
| Mar 31, 2014 | 585,936.00 |
| Dec 31, 2013 | 164,044.00 |
| Sep 30, 2013 | 190,663.00 |
| Jun 30, 2013 | 249,845.00 |